Relay Therapeutics (RLAY) FCF Margin (2021 - 2026)
Relay Therapeutics (RLAY) reported FCF Margin of 1703.73% for Q1 2026, down 74535.0% year-over-year from N/an in Q1 2025, and down 165.82% quarter-over-quarter from 640.94% in Q4 2025.
Relay Therapeutics (RLAY) FCF Margin (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 6 years of FCF Margin data on file, last reported at 1703.73% in Q1 2026.
- FCF Margin for Q1 2026 came in at 1703.73%, down 74535.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1998.53% (up 155162.0% YoY), and the FY2025 annual result was 1536.08%, up 97341.0% from the prior year.
- FCF Margin declined to 1703.73% in Q1 2026 per RLAY's latest filing, from 640.94% in the prior quarter.
- Over five years, FCF Margin peaked at 8930600.0% in Q4 2023 and troughed at 58910.92% in Q2 2023.
- A 5-year average of 673613.82% and a median of 8166.47% in 2025 frame the typical range for FCF Margin.
- On a YoY basis, FCF Margin climbed as much as 895407628 bps in 2023 and fell as far as 4276024 bps in 2023.
- A 5-year view of FCF Margin shows it stood at 23476.28% in 2022, then surged by 38141 bps to 8930600.0% in 2023, then plunged by 100 bps to 520.67% in 2024, then slipped by 23 bps to 640.94% in 2025, then plunged by 166 bps to 1703.73% in 2026.
- Business Quant data shows RLAY's FCF Margin at 1703.73% in Q1 2026, 640.94% in Q4 2025, and 8166.47% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relay Therapeutics | 2.86 Bn | 2.86 Bn | - | -1,703.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,703.73% |
| Dec 31, 2025 | -640.94% |
| Jun 30, 2025 | -8,166.47% |
| Mar 31, 2025 | -958.38% |
| Mar 31, 2024 | -520.67% |
| Dec 31, 2023 | 8,930,600.00% |
| Sep 30, 2023 | -301.51% |
| Jun 30, 2023 | -58,910.92% |
| Mar 31, 2023 | -30,550.88% |
| Dec 31, 2022 | -23,476.28% |
| Sep 30, 2022 | -19,837.21% |
| Jun 30, 2022 | -16,150.68% |
| Mar 31, 2022 | -12,402.63% |
| Dec 31, 2021 | -7,158.20% |
| Sep 30, 2021 | -8,215.17% |
| Jun 30, 2021 | -3,449.88% |
| Mar 31, 2021 | 4,888.66% |